Risa Goto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Risa Goto has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Tomoyuki Aruga
Institute of Science Tokyo
2 shared publications - Chiaki Saita
Division of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan
1 shared publication - Dai Kitagawa
Takahito Suemasu, MD, Department of Breast and Endocrine Surgery, National Center for Global Health and Medicine, Tokyo, Japan; Akihiko Shimomura, MD, PhD, and Chikako Shimizu, MD, PhD, Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Tokyo, Japan; and Kazuki Hashimoto, MD, and Dai Kitagawa, MD, PhD, Department of Breast and Endocrine Surgery, National Center for Global Health and Medicine, Tokyo, Japan
1 shared publication Hiromi Miyamoto
Division of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
1 shared publication- Hiromi Miyamoto
Department of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Tokyo, Japan
1 shared publication Katsumasa Kuroi
Division of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
1 shared publication
Latest Publications
- 13 January 2020
- Published by Springer Nature in Breast Cancer
- Vol. 27 (4) , 586-593
The number of FoxP3-positive tumor-infiltrating lymphocytes in patients with synchronous bilateral breast cancer
In breast cancer, FoxP3-positive tumor-infiltrating lymphocytes (FoxP3+ TILs) vary depending on lymph node status, histological grade, and subtype. All these studies have compared the numbers of FoxP3+ TILs among different hosts, but recruitment of FoxP3+ TILs might depend on each individual’s immune environment and each tumor’s biological characteristics. In the present study, FoxP3+ TIL numbers were investigated in patients with synchronous bilateral breast cancer (SBBC) to determine the factors that affect FoxP3+ TIL recruitment in the same anti-tumor immune environment.
- 13 January 2020
- Published by Springer Nature in Breast Cancer
- Vol. 27 (4) , 586-593
The number of FoxP3-positive tumor-infiltrating lymphocytes in patients with synchronous bilateral breast cancer
In breast cancer, FoxP3-positive tumor-infiltrating lymphocytes (FoxP3+ TILs) vary depending on lymph node status, histological grade, and subtype. All these studies have compared the numbers of FoxP3+ TILs among different hosts, but recruitment of FoxP3+ TILs might depend on each individual’s immune environment and each tumor’s biological characteristics. In the present study, FoxP3+ TIL numbers were investigated in patients with synchronous bilateral breast cancer (SBBC) to determine the factors that affect FoxP3+ TIL recruitment in the same anti-tumor immune environment.
- Open Access
- 26 January 2016
- Published by Springer Nature in BMC Research Notes
- Vol. 9 (1) , 46
Invasive papillary carcinoma treated with neoadjuvant endocrine therapy in which pathological complete response was achieved
Invasive papillary carcinoma is a rare type of invasive ductal carcinoma. Neoadjuvant endocrine therapy is now considered as an optional therapy for postmenopausal women with hormone receptor-positive breast cancers, including invasive papillary carcinoma. We discuss the case of an 83-year-old postmenopausal Japanese female with hormone receptor-positive invasive papillary carcinoma who started treatment with an aromatase inhibitor and achieved pathological complete response after 12 months of endocrine treatment. Appropriate drugs and durations of neoadjuvant endocrine treatment have yet to be established. Continuing therapy with an aromatase inhibitor until the best clinical response is achieved may represent one of the best strategies in neoadjuvant endocrine therapy.
- 26 January 2016
- Published by Springer Nature in BMC Research Notes
- Vol. 9 (1) , 46
Open AccessInvasive papillary carcinoma treated with neoadjuvant endocrine therapy in which pathological complete response was achieved
Invasive papillary carcinoma is a rare type of invasive ductal carcinoma. Neoadjuvant endocrine therapy is now considered as an optional therapy for postmenopausal women with hormone receptor-positive breast cancers, including invasive papillary carcinoma. We discuss the case of an 83-year-old postmenopausal Japanese female with hormone receptor-positive invasive papillary carcinoma who started treatment with an aromatase inhibitor and achieved pathological complete response after 12 months of endocrine treatment. Appropriate drugs and durations of neoadjuvant endocrine treatment have yet to be established. Continuing therapy with an aromatase inhibitor until the best clinical response is achieved may represent one of the best strategies in neoadjuvant endocrine therapy.
- 1 October 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25 (suppl_5) , v103-v104
Prognostic Significance of Subtypes and Gpa(Graded Prognostic Assessment) in Brain Metastases From Breast Cancer
Background: It is known that age, KPS and subtype are important prognostic factors, and the Graded Prognostic Assessment (GPA) has been previously reported to clarify prognosis for brain metastases (BM) patients by the other investigators. Method: Sixty-six patients with BM were included. We examined the clinical characteristics by primary tumor subtype; ER + /HER2- (LM), ER + or-/HER2+ (Her2-potitive), ER-/HER2- (TN), and GPS scores were calculated according to Breast cancer specific GPA (BCS-GPA). Results: The number of LM, Her2-positive, TN tumors were 26, 21, 19, respectively. In patients with Her2-positive tumors, the number of brain metastasis tended to be single and there were only a few patients with meningitis. Median survival after BM in patients with LM, Her2-positive, TN tumors were 11, 37, 3 months, respectively. Prognosis of patients with TN tumors was significantly poor (vs. Her2 p < 0.001), and prognosis of patients with Her2-positive tumors tended to be longer as compared with those with LM (p = 0.188). GPA scores were 0-1 in 8 cases, 1.5-2 in 19 cases, 2.5-3 were 24 cases, 3.5-4were 15 cases, and median survivals were 3, 8, 10, 40 months, respectively. Conclusions: Our reports suggested that the pattern and prognosis of BM appear to be dependent on subtype and GPA score would have prognostic significance and might be useful for decision making.
- 1 October 2014
- Published by Elsevier in Annals of Oncology
- Vol. 25 (suppl_5) , v103-v104
Prognostic Significance of Subtypes and Gpa(Graded Prognostic Assessment) in Brain Metastases From Breast Cancer
Background: It is known that age, KPS and subtype are important prognostic factors, and the Graded Prognostic Assessment (GPA) has been previously reported to clarify prognosis for brain metastases (BM) patients by the other investigators. Method: Sixty-six patients with BM were included. We examined the clinical characteristics by primary tumor subtype; ER + /HER2- (LM), ER + or-/HER2+ (Her2-potitive), ER-/HER2- (TN), and GPS scores were calculated according to Breast cancer specific GPA (BCS-GPA). Results: The number of LM, Her2-positive, TN tumors were 26, 21, 19, respectively. In patients with Her2-positive tumors, the number of brain metastasis tended to be single and there were only a few patients with meningitis. Median survival after BM in patients with LM, Her2-positive, TN tumors were 11, 37, 3 months, respectively. Prognosis of patients with TN tumors was significantly poor (vs. Her2 p < 0.001), and prognosis of patients with Her2-positive tumors tended to be longer as compared with those with LM (p = 0.188). GPA scores were 0-1 in 8 cases, 1.5-2 in 19 cases, 2.5-3 were 24 cases, 3.5-4were 15 cases, and median survivals were 3, 8, 10, 40 months, respectively. Conclusions: Our reports suggested that the pattern and prognosis of BM appear to be dependent on subtype and GPA score would have prognostic significance and might be useful for decision making.